APA (7th ed.) Citation

Colbert, L., Jia, Y., Sharma, A., Hu, J., Xu, Z., Suzman, D. L., . . . Fashoyin-Aje, L. A. (2025). FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer. Clinical cancer research, 31(7), 1182-1185. https://doi.org/10.1158/1078-0432.CCR-24-2812

Chicago Style (17th ed.) Citation

Colbert, Laronna, et al. "FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer." Clinical Cancer Research 31, no. 7 (2025): 1182-1185. https://doi.org/10.1158/1078-0432.CCR-24-2812.

MLA (9th ed.) Citation

Colbert, Laronna, et al. "FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer." Clinical Cancer Research, vol. 31, no. 7, 2025, pp. 1182-1185, https://doi.org/10.1158/1078-0432.CCR-24-2812.